FierceBiotech 2026-03-02 Boehringer axes MASH deal with OSE as biotech continues to whittle down pipeline
FierceBiotech 2026-03-02 BioAtla lays off 70% of workforce, searches for buyers for antibody pipeline
FierceBiotech 2026-03-02 United Therapeutics’ phase 3 win tees up filing to challenge J&J in cardiac condition
FierceBiotech 2026-03-02 UniQure shares crash 40% as FDA rejects early approval path for Huntington's gene therapy
FierceBiotech 2026-03-02 Aardvark pauses phase 3 metabolic drug study over 'cardiac observations,' sinking sock
FierceBiotech 2026-03-02 Roche reports another phase 3 multiple sclerosis win, but deaths add to safety questions
FierceBiotech 2026-02-28 BioNTech advances DualityBio ADC into phase 3 with half the patients of Merck-Daiichi rival
FierceBiotech 2026-02-27 Atrium arises from Novartis' Avidity buy with $270M, pair of preclinical cardio candidates
FierceBiotech 2026-02-27 Lilly debuts Nvidia supercomputer with fanfare and focus on escaping traditional pharma lifecycle
FierceBiotech 2026-02-27 FDA slams ExThera with warning letter over controversial blood filter device
FierceBiotech 2026-02-27 As CAR-T cell therapy gains ground on solid tumors, regulatory red tape hinders progress
FierceBiotech 2026-02-27 'Like talking to a brick wall': Senate hearing takes aim at FDA's rare disease review process
FierceBiotech 2026-02-26 Sarepta CEO Doug Ingram to retire after a decade of Duchenne breakthroughs and controversies
FierceBiotech 2026-02-26 Analysts see potential in MDMA drug after AtaiBeckley reports improvements in anxiety trial